ClinicalTrials.gg
CompletedNCT00630058Updated Jan 6, 2026Results posted

A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

A Phase 1 interventional study of MP-424(H), PEG-IFN-a-2b, RBV and MP-424 (L), PEG-IFN-a-2b, RBV in Hepatitis C, sponsored by Tanabe Pharma Corporation. Completed at 1 site in Japan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Tanabe Pharma Corporation · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing telaprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C.

Enrollment
25th of 39
20 · median 30
Started
2008
with 7 others
Phase 1
12 of 39
none open now
Registered
8th of 39
by date
Lead sponsor
4 of 39
Tanabe Pharma Corporation

Among the 39 studies testing telaprevir in Hepatitis C, this one is the 25th largest by enrollment, is one of 8 that started in 2008, is one of 12 in phase 1, and was the 8th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 39 studies testing telaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About telaprevir

telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing telaprevir in Hepatitis C as a file.
02

Study summary

The purpose of this study is to assess the safety, pharmacokinetics, HCV RNA kinetics, and other viral characteristics after administration of two arms of MP-424 in combination with Peginterferon Alfa 2b (PEG-IFN-a-2b) and Ribavirin (RBV) to patients with chronic hepatitis C.

03

Conditions studied

  • Hepatitis C

Keywords

  • Chronic Hepatitis C
  • Protease Inhibitor
  • Telaprevir
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with genotype 1b chronic

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with decompensated cirrhosis
  • Patients diagnosed with positive HBs antigen in the test
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Group A (MP-424 High)

    Drug: MP-424(H), PEG-IFN-a-2b, RBV

  • Experimental
    Group B (MP-424 Low)

    Drug: MP-424 (L), PEG-IFN-a-2b, RBV

Interventions

  • DrugMP-424(H), PEG-IFN-a-2b, RBV

    Drug pages: Telaprevir · Peginterferon alfa-2b · Ribavirin

    MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks

    Also known as: Telaprevir

  • DrugMP-424 (L), PEG-IFN-a-2b, RBV

    Drug pages: Telaprevir · Peginterferon alfa-2b · Ribavirin

    MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks

    Also known as: Telaprevir

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum Observed Concentration in Plasma) of MP-424

    Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.

    Time frame: Data were collected at Day1 to Day85

  2. Tmax (Time of Maximum Concentration in Plasma) of MP-424

    Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.

    Time frame: Data were collected at Day1 to Day85

  3. AUC 0-8h (Area Under the Concentration-time Curve From Time Zero to 8 Hours) of MP-424

    Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.

    Time frame: Data were collected at Day1 to Day85

  4. Ctrough (Minimum Observed Concentration in Plasma) of MP-424

    Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.

    Time frame: Data were collected at Day1 to Day85

  5. T1/2(Time of Half-Life) of MP-424

    Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.

    Time frame: Data were collected at Day1 to Day85

Secondary outcomes

  1. Antiviral Effects of TVR on HCV Were Assessed by Measuring Plasma HCV RNA Levels

    HCV RNA concentrations were determined using the COBAS TaqMan HCV test (Roche Diagnostics). The linear dynamic range of the assay was 1.2-7.8 log10 IU/mL.

    Time frame: 37 weeks

07

Results

Posted Jan 18, 2013

Participant flow

Participant flow — Overall Study
MilestoneGroup A (MP-424 High)Group B (MP-424 Low)
Started1010
Completed66
Not completed44
Withdrew: Adverse event11
Withdrew: Withdrawal by subject01
Withdrew: Stopping criteria32

Outcome measures

PrimaryCmax (Maximum Observed Concentration in Plasma) of MP-424

Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.

Time frame:
Data were collected at Day1 to Day85
Reported as:
Mean · μg/mL
Cmax (Maximum Observed Concentration in Plasma) of MP-424
μg/mLGroup A (MP-424 High)Group B (MP-424 Low)
Day 1 (Group A,B:10 cases)1.62 ± 0.431.45 ± 0.83
Day 14 (Group A,B:10 cases)3.96 ± 1.103.06 ± 0.90
Day 85 (Group A: 6 cases, Group B: 7 cases)3.67 ± 0.873.16 ± 1.10
PrimaryTmax (Time of Maximum Concentration in Plasma) of MP-424

Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.

Time frame:
Data were collected at Day1 to Day85
Reported as:
Median · hours
Tmax (Time of Maximum Concentration in Plasma) of MP-424
hoursGroup A (MP-424 High)Group B (MP-424 Low)
Day 1 (Group A, B:10 cases)2.51 (2.25 to 6.00)2.54 (2.33 to 8.02)
Day 14 (Group A, B:10 cases)2.50 (2.42 to 5.75)2.45 (2.33 to 6.00)
Day 85 (Group A: 6 cases, Group B: 7 cases)3.24 (2.35 to 7.75)2.43 (2.33 to 4.00)
PrimaryAUC 0-8h (Area Under the Concentration-time Curve From Time Zero to 8 Hours) of MP-424

Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.

Time frame:
Data were collected at Day1 to Day85
Reported as:
Mean · μg/mL
AUC 0-8h (Area Under the Concentration-time Curve From Time Zero to 8 Hours) of MP-424
μg/mLGroup A (MP-424 High)Group B (MP-424 Low)
Day 1 (Group A, B: 10 cases)7.53 ± 1.936.55 ± 3.73
Day 14 (Group A: 9 cases, Group B: 10 cases)26.00 ± 6.7719.94 ± 5.97
Day 85 (Group A: 6 cases, Group B: 7 cases)25.00 ± 5.2321.35 ± 6.88
PrimaryCtrough (Minimum Observed Concentration in Plasma) of MP-424

Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.

Time frame:
Data were collected at Day1 to Day85
Reported as:
Mean · μg/mL
Ctrough (Minimum Observed Concentration in Plasma) of MP-424
μg/mLGroup A (MP-424 High)Group B (MP-424 Low)
Day1 (Group A,B: 10 cases)0.846 ± 0.5000.681 ± 0.412
Day14 (Group A: 9 cases, Group B:10cases)2.639 ± 0.5561.914 ± 0.717
Day85 (Group A: 6 cases, Group B:7cases)2.679 ± 0.3552.105 ± 0.819
PrimaryT1/2(Time of Half-Life) of MP-424

Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.

Time frame:
Data were collected at Day1 to Day85
Reported as:
Mean · hours
T1/2(Time of Half-Life) of MP-424
hoursGroup A (MP-424 High)Group B (MP-424 Low)
Day1 (Group A: 7 cases, Group B: 8 cases)4.87 ± 2.124.03 ± 1.63
Day14 (Group A: 8 cases, Group B: 9 cases)9.99 ± 4.3710.00 ± 6.97
Day85 (Group A: 6 cases, Group B: 7 cases)9.06 ± 3.986.22 ± 3.64
SecondaryAntiviral Effects of TVR on HCV Were Assessed by Measuring Plasma HCV RNA Levels

HCV RNA concentrations were determined using the COBAS TaqMan HCV test (Roche Diagnostics). The linear dynamic range of the assay was 1.2-7.8 log10 IU/mL.

Time frame:
37 weeks
Reported as:
Mean · Log IU / mL
Antiviral Effects of TVR on HCV Were Assessed by Measuring Plasma HCV RNA Levels
Log IU / mLGroup A (MP-424 High)Group B (MP-424 Low)
Day 1_2.5h (Group A,B: 10 cases)-0.190 ± 0.235-0.220 ± 0.329
Day 1_4h (Group A,B: 10 cases)-0.420 ± 0.264-0.390 ± 0.378
Day 1_8h (Group A,B: 10 cases)-1.300 ± 0.294-1.310 ± 0.309
Day 1_16h (Group A,B: 10 cases)-2.350 ± 0.458-2.480 ± 0.286
Day 2 (Group A,B: 10 cases)-3.010 ± 0.340-3.180 ± 0.220
Day 3 (Group A,B: 10 cases)-3.610 ± 0.453-3.790 ± 0.407
Day 8 (Group A,B: 10 cases)-4.840 ± 0.622-5.010 ± 0.551
Day 14 (Group A,B: 10 cases)-5.570 ± 0.579-5.800 ± 0.554
Day 29 (Group A: 10 cases, Group B: 9 cases)-5.860 ± 0.611-5.978 ± 0.519
Day 43 (Group A: 8 cases, Group B: 8 cases)-6.000 ± 0.573-5.994 ± 0.590
Day 57 (Group A: 7 cases, Group B: 8 cases)-5.986 ± 0.538-5.994 ± 0.539
Day 86 (Group A: 6 cases, Group B: 7 cases)-6.000 ± 0.588-6.114 ± 0.609
Day 92 (Group A: 6 cases, Group B: 7 cases)-6.000 ± 0.588-6.114 ± 0.609
Day 99 (Group A: 6 cases, Group B: 7 cases)-6.000 ± 0.588-5.471 ± 1.065
Day 113 (Group A: 6 cases, Group B: 7 cases)-5.917 ± 0.564-3.457 ± 2.591
Day 141 (Group A: 6 cases, Group B: 7 cases)-4.233 ± 2.455-3.000 ± 2.865
Day 169 (Group A: 6 cases, Group B: 6 cases)-3.100 ± 2.827-3.267 ± 3.067
Day 197 (Group A: 6 cases, Group B: 6 cases)-2.850 ± 2.947-3.283 ± 3.031
Day 225 (Group A: 6 cases, Group B: 6 cases)-2.633 ± 2.748-3.183 ± 3.140
Day 253 (Group A: 6 cases, Group B: 6 cases)-1.883 ± 3.177-3.100 ± 3.234

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A (MP-424 High)—2/10 (20%)10/10 (100%)
Group B (MP-424 Low)—2/10 (20%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventGroup A (MP-424 High)Group B (MP-424 Low)
AnaemiaBlood and lymphatic system disorders1/101/10
Appetite disordersMetabolism and nutrition disorders0/101/10
DizzinessNervous system disorders0/101/10
VertigoEar and labyrinth disorders1/100/10
Drug eruptionSkin and subcutaneous tissue disorders0/101/10
Most frequent other events
Showing 10 of 107
Most frequent other events
EventGroup A (MP-424 High)Group B (MP-424 Low)
Platelet count decreasedInvestigations10/1010/10
White blood cell count decreasedInvestigations9/1010/10
AnaemiaBlood and lymphatic system disorders9/108/10
PyrexiaGeneral disorders6/108/10
Protein total decreasedInvestigations0/108/10
HeadacheNervous system disorders3/107/10
RashSkin and subcutaneous tissue disorders7/107/10
Blood lactate dehydrogenase increasedInvestigations3/107/10
MalaiseGeneral disorders6/105/10
Blood triglycerides increasedInvestigations6/105/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group A (MP-424 High)Group B (MP-424 Low)Total
Mean50.1 ± 6.854.3 ± 8.552.2 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Group A (MP-424 High)Group B (MP-424 Low)Total
Female4610
Male6410
08

Study locations

1 site
  • Toranomon Hospital
    Kawasaki, Takatsu-ku, Japan
09

References and documents

Publications

  • Suzuki F, Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, Kumada H. Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. Hepatol Res. 2013 Jul;43(7):691-701. doi: 10.1111/hepr.12009. Epub 2012 Nov 29. PubMed 23190247 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2008
First posted
Mar 6, 2008
Start
Apr 2008
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Jan 18, 2013
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00630058
Responsible party
Sponsor
First posted
Mar 6, 2008
Start date
Apr 2008
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Jan 18, 2013
Last update
Jan 6, 2026

Study contacts

Fumitaka Suzuki, MD
principal investigator · Department of Hepatology, Toranomon Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telaprevir · Peginterferon alfa-2b · Ribavirin

Start the discussion